Yoshimitsu Soga1, Osamu Iida2
1Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan; 2Kansai Rosai Hospital, Amagasaki, Japan.
OBJECTIVES: To compared the effects of beta blockers in patient undergoing femoropopliteal stenting.
METHODS: This study was a multicenter retrospective registry of prospectively maintained database. Between January 2004 and December 2011, 438 patients (532 limbs) who treated by carvedilol (187 patients, 229 limbs) or bisoprolol (251 patients, 303 limbs) were identified and analyzed. The endpoints of this study were primary and secondary patency, overall survival and freedom from major adverse limb events (MALE; includes any repeat revascularization and major amputation). The mean follow-up period was 27+/-17 months.
RESULTS: Primary patency was significantly higher in the bisoprolol-treated group than in the carvedilol-treated group (71.7% vs. 55.9% at 3-year, p=0.0006). Secondary patency and freedom from MALE were also significantly higher in the bisoprolol-treated group (92.7% vs. 76.1% at 3-year, p=0.0004 and 75.2% vs. 58.0% at 3-year, p<0.0001, respectively). However, overall survival was similar between both groups (82.0% vs. 82.6% at 3-year, p=0.44). After correcting with baseline variables, bisoprolol was found to be effective for primary patency (Hazard ratio 0.56, 95% confidential interval 0.37 to 0.83, adjusted p=0.005).
CONCLUSIONS: In the vessel patency and the incidence of MALE after femoropopliteal stenting, patients in whom bisoprolol was given experienced better than those in whom carvedilol was given.
AUTHOR DISCLOSURES: O. Iida:
Nothing to disclose; Y. Soga:
Nothing to disclose.
Primary patency after femoropopliteal stenting in patients with bisoprolol and with carvedilol.
Posted April 2013